Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies

被引:3
作者
Lopez-Campos, Jose Luis
Hernandez, Laura Carrasco
Ruiz-Duque, Borja
Reinoso-Arija, Rocio
Caballero-Eraso, Candelaria
机构
[1] Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla IBiS, Unidad Med Quirurg Enfermedades Resp, Seville, Spain
[2] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
关键词
COPD; escalation of treatment; pharmacological therapies; precision medicine; OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; POST-HOC ANALYSIS; OF-LIFE CARE; INHALED CORTICOSTEROIDS; LUNG-FUNCTION; BLOOD EOSINOPHILS; EXACERBATIONS; ASTHMA; TIOTROPIUM;
D O I
10.2147/COPD.S275943
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Recent advances in inhaled drugs and a clearer definition of the disease have made the task of managing COPD more complex. Different proposals have been put forward which combine all the available treatments and the different clinical presentations in an effort to select the best therapeutic options for each clinical context. As COPD is a chronic progressive disease, the escalation of therapy has traditionally been considered the most natural way to tackle it. However, the notion of COPD as a constantly progressing disease has recently been challenged and, in specific areas, this points to the possibility of a deescalation in treatment. In this context, the clinician requires simple, specific recommendations to guide these changes in treatment in their daily clinical practice. To accomplish this, the first step must be a correct evaluation and an accurate initial preliminary diagnosis of the patient's condition. Thereafter, the first escalation in therapy must be introduced with caution as the disease progresses, since clinical trials are not designed with clinical decision-making in mind. During this escalation, three possibilities are open to change the current treatment for a different one within the same family, to increase non-pharmacological interventions or to increase the pharmacological therapies. Beyond that point, a patient with persistent symptoms represents a complex clinical scenario which requires a specialized approach, including the evaluation of different respiratory and non-respiratory comorbidities. Unfortunately, there are few de-escalation studies available, and these are mainly observational in nature. The debate on de-escalation in pharmacological treatment, therefore, involves two main discussion points: the withdrawal of bronchodilators and the withdrawal of inhaled steroids. Altogether, the scheme for modifying treatment must be more personalized than just adding molecules, and the therapeutic response and its conditioning factors should be evaluated at each step before proceeding further.
引用
收藏
页码:2065 / 2076
页数:12
相关论文
共 88 条
[1]   Community Assessment of COPD Health Care (COACH) study: a clinical audit on primary care performance variability in COPD care [J].
Abad-Arranz, Maria ;
Moran-Rodriguez, Ana ;
Mascaros Balaguer, Enrique ;
Quintana Velasco, Carmen ;
Abad Polo, Laura ;
Nunez Palomo, Sara ;
Gonzalvez Rey, Jaime ;
Fernandez Vargas, Ana Maria ;
Hidalgo Requena, Antonio ;
Helguera Quevedo, Jose Manuel ;
Garcia Pardo, Marina ;
Luis Lopez-Campos, Jose .
BMC MEDICAL RESEARCH METHODOLOGY, 2018, 18
[2]   The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) [J].
Albertson, Timothy E. ;
Chenoweth, James A. ;
Pearson, Skyler J. ;
Murin, Susan .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (02) :213-231
[3]   Alveolar and Bronchial Nitric Oxide in Chronic Obstructive Pulmonary Disease and Asthma-COPD Overlap [J].
Alcazar-Navarrete, Bernardino ;
Castellano Minan, Francisca ;
Santiago Diaz, Pablo ;
Ruiz Rodriguez, Oliveiro ;
Romero Palacios, Pedro J. .
ARCHIVOS DE BRONCONEUMOLOGIA, 2018, 54 (08) :414-419
[4]   Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD [J].
Alcazar-Navarrete, Bernardino ;
Ruiz Rodriguez, Oliverio ;
Conde Baena, Pablo ;
Romero Palacios, Pedro Jose ;
Agusti, Alvar .
EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (01)
[5]  
Ancochea J, 2020, ARCH BRONCONEUMOL
[6]   Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer [J].
Au, DH ;
Udris, EM ;
Fihn, SD ;
McDonell, MB ;
Curtis, JR .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (03) :326-331
[7]   Skeletal Muscle Dysfunction in COPD: Novelties in The Last Decade [J].
Barreiro, Esther .
ARCHIVOS DE BRONCONEUMOLOGIA, 2017, 53 (02) :43-44
[8]  
Cabrera Lopez C, 2020, ARCH BRONCONEUMOL
[9]   Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study [J].
Calle Rubio, Myriam ;
Luis Lopez-Campos, Jose ;
Soler-Cataluna, Juan J. ;
Alcazar Navarrete, Bernardino ;
Soriano, Joan B. ;
Rodriguez Gonzalez-Moro, Jose Miguel ;
Fuentes Ferrer, Manuel E. ;
Rodriguez Hermosa, Juan Luis .
RESPIRATORY RESEARCH, 2017, 18
[10]   Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study [J].
Calle Rubio, Myriam ;
Alcazar Navarrete, Bernardino ;
Soriano, Joan B. ;
Soler-Cataluna, Juan J. ;
Rodriguez Gonzalez-Moro, Jose Miguel ;
Fuentes Ferrer, Manuel E. ;
Luis Lopez-Campos, Jose .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 :417-426